Compare JBSS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | SPRY |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.0M | 823.2M |
| IPO Year | 1994 | 2020 |
| Metric | JBSS | SPRY |
|---|---|---|
| Price | $76.54 | $8.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $109.00 | $40.00 |
| AVG Volume (30 Days) | 90.7K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $1,107,246,000.00 | $84,278,000.00 |
| Revenue This Year | $5.58 | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $16.74 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $59.07 | $6.66 |
| 52 Week High | $85.15 | $18.63 |
| Indicator | JBSS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 49.40 |
| Support Level | $74.15 | $7.82 |
| Resistance Level | $77.50 | $8.61 |
| Average True Range (ATR) | 2.32 | 0.55 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 36.63 | 42.91 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.